Next generation lactamase inhibitors

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: 2600506

Grant search

Key facts

  • Disease

    Bacterial infection caused by Klebsiella pneumonia
  • Start & end year

    2021
    2025
  • Known Financial Commitments (USD)

    $0
  • Funder

    UK Research and Innovation (UKRI)
  • Principal Investigator

    N/A

  • Research Location

    United Kingdom
  • Lead Research Institution

    UNIVERSITY OF OXFORD
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The 3-lactamase enzymes degrade 3-lactam antibiotics, exemplified by penicillin. As such, the families of metallo- and serine 3-lactamase enzymes are responsible for a major antimicrobial resistance mechanism in many clinically relevant species of Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. To preserve the antimicrobial activity of 3-lactam antibiotics, inhibitors of 3-lactamases can be used in combination with a 3-lactam antibiotic during treatment of an antimicrobial resistant infection. However, these inhibitors often have a narrow spectrum of activity against 3-lactamases, and other bacterial mechanisms of resistance against them. This project aims to investigate the structure-activity relationships of various serine 3-lactamases with different commercially available and in-house developed 3-lactamase substrates and 3-lactamase inhibitors. In particular, this project will use time-resolved serial crystallography techniques, as well as other spectroscopic and spectrometric techniques. Data derived from these studies will be used for the rational design of novel 3-lactamase inhibitors. UKRI-BBSRC priority areas addressed: Combatting antimicrobial resistance